DEA will not initiate rescheduling proceedings for psilocybin or MDMA independent of FDA action before 2026-12-31.

The DEA (the US drug enforcement agency) will wait for the FDA (the US medicine regulator) to act first before it reclassifies psilocybin or MDMA. This matters because DEA action could unlock medical use and research, but the DEA has no track record of moving independently on drugs — it watches for FDA approval first to avoid legal and political risk.

DEA has structural and political incentives to wait for FDA: it avoids legal exposure, retains law enforcement credibility, and has active support from law enforcement lobby groups. No historical precedent exists for DEA-initiated psychedelic rescheduling absent FDA recommendation. Falsifiable: would resolve NO if DEA publishes a Notice of Proposed Rulemaking for either substance without a prior FDA recommendation.